Abiopharma

As previously reported on June 16, 2022, the trial d. The study evaluated the potential of the anti-amyloid beta antibody crenezumab to slow or prevent Alzheimers disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimers disease.